MAP2K7 and Papillary Craniopharyngioma: Alternatively, one case report of a single patient’s experience describes empiric treatment with BRAF/MEK inhibition alone of a presumed papillary craniopharyngioma with excellent radiographic and neuroendocrinologic outcomes [17].